NO20091211L - Farmasoytiske clonazepamformuleringer og fremgangsmate for disse - Google Patents
Farmasoytiske clonazepamformuleringer og fremgangsmate for disseInfo
- Publication number
- NO20091211L NO20091211L NO20091211A NO20091211A NO20091211L NO 20091211 L NO20091211 L NO 20091211L NO 20091211 A NO20091211 A NO 20091211A NO 20091211 A NO20091211 A NO 20091211A NO 20091211 L NO20091211 L NO 20091211L
- Authority
- NO
- Norway
- Prior art keywords
- solvent
- benzodiazepine
- present
- pharmaceutical
- relates
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
- A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0043—Nose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Neurology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Otolaryngology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Anesthesiology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
Den foreliggende oppfinnelse vedrører benzodiazepinblandinger formulert for nasal administrering inneholdende et binært løsningsmiddelsystem omfattende et første løsningsmiddel hvori benzodiazepinet er løselig, idet det første løsningsmiddel er i stand til å trenge gjennom neseslimhinnevev, og et andre løsningsmiddel hvori benzodiazepinet er mindre løselig. Blandingene ifølge den foreliggende oppfinnelse kan anvendes for å behandle en rekke forstyrrelser omfattende, men ikke begrenset til, panikkanfall, muskelspasmer, angst og anfall. I ett aspekt vedrører den foreliggende oppfinnelse en hurtigvirkende blanding for transnasal administrering som kan brukes for. behandling av anfall-clustere.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US84056806P | 2006-08-28 | 2006-08-28 | |
PCT/US2007/018877 WO2008027357A2 (en) | 2006-08-28 | 2007-08-27 | Pharmaceutical compositions of clonazepam and methods of use thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
NO20091211L true NO20091211L (no) | 2009-05-27 |
Family
ID=38819711
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO20091211A NO20091211L (no) | 2006-08-28 | 2009-03-23 | Farmasoytiske clonazepamformuleringer og fremgangsmate for disse |
Country Status (17)
Country | Link |
---|---|
US (2) | US8609651B2 (no) |
EP (2) | EP2068933A2 (no) |
JP (2) | JP2010502612A (no) |
KR (1) | KR20090043603A (no) |
CN (1) | CN101528261B (no) |
AR (1) | AR062556A1 (no) |
AU (1) | AU2007290589B2 (no) |
BR (1) | BRPI0714907A2 (no) |
CA (1) | CA2662197A1 (no) |
IL (1) | IL197275A0 (no) |
MX (1) | MX2009002310A (no) |
NO (1) | NO20091211L (no) |
NZ (2) | NZ595388A (no) |
PE (1) | PE20081361A1 (no) |
TW (1) | TW200824693A (no) |
UY (1) | UY30561A1 (no) |
WO (2) | WO2008027395A2 (no) |
Cited By (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11400065B2 (en) | 2019-03-01 | 2022-08-02 | Flamel Ireland Limited | Gamma-hydroxybutyrate compositions having improved pharmacokinetics in the fed state |
US11504347B1 (en) | 2016-07-22 | 2022-11-22 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
US11602513B1 (en) | 2016-07-22 | 2023-03-14 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
US11602512B1 (en) | 2016-07-22 | 2023-03-14 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
US11779557B1 (en) | 2022-02-07 | 2023-10-10 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
US11839597B2 (en) | 2016-07-22 | 2023-12-12 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
US11986451B1 (en) | 2016-07-22 | 2024-05-21 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
Families Citing this family (26)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TW200824693A (en) | 2006-08-28 | 2008-06-16 | Jazz Pharmaceuticals Inc | Pharmaceutical compositions of clonazepam and methods of use thereof |
DK2121025T3 (en) * | 2007-01-19 | 2017-01-30 | Hananja Ehf | Methods and compositions for delivering a therapeutic agent |
US20080275030A1 (en) * | 2007-01-19 | 2008-11-06 | Sveinbjorn Gizurarson | Methods and Compositions for the Delivery of a Therapeutic Agent |
TW200922635A (en) * | 2007-08-31 | 2009-06-01 | Archimedes Dev Ltd | Non-aqueous pharmaceutical compositions |
GB0716907D0 (en) * | 2007-08-31 | 2007-10-10 | Archimedes Dev Ltd | Pharmaceutical powder compositions |
AU2009228093B2 (en) * | 2008-03-28 | 2014-08-07 | Neurelis, Inc. | Administration of benzodiazepine compositions |
KR101517415B1 (ko) * | 2008-05-14 | 2015-05-07 | 에스케이바이오팜 주식회사 | 난용성 항경련제를 함유하는 경비 항경련성 약학 조성물 |
WO2010126970A1 (en) * | 2009-04-28 | 2010-11-04 | Optmed, Inc. | Methods for treating and preventing erectile dysfunction |
JP2012525402A (ja) * | 2009-04-28 | 2012-10-22 | オプトメッド インコーポレイテッド | 過活動膀胱およびそれに関連する状態を、治療するおよび予防するための、組成物および方法 |
GB2481407B (en) * | 2010-06-22 | 2012-05-23 | Special Products Ltd | A rapid onset liquid midazolam composition for buccal administration |
EP2691100A4 (en) * | 2011-03-31 | 2014-09-24 | Acorda Therapeutics Inc | INTRANASAL PHARMACEUTICAL COMPOSITIONS OF BENZODIAZEPINE |
ES2683902T3 (es) | 2011-06-14 | 2018-09-28 | Hale Biopharma Ventures, Llc | Administración de benzodiacepina |
WO2013090278A2 (en) | 2011-12-11 | 2013-06-20 | Recro Pharma, Inc. | Intranasal dexmedetomidine compositions and methods of use thereof |
US9125805B2 (en) * | 2012-06-27 | 2015-09-08 | Xeris Pharmaceuticals, Inc. | Stable formulations for parenteral injection of small molecule drugs |
US8999393B1 (en) * | 2013-01-09 | 2015-04-07 | Edgemont Pharmaceuticals Llc | Sustained release formulations of lorazepam |
US20160000702A1 (en) * | 2013-02-22 | 2016-01-07 | Eastgate Pharmaceuticals Inc. | Pharmaceutical composition for enhanced transmucosal adminstration of benzodiazepines |
KR101635635B1 (ko) * | 2014-12-04 | 2016-07-01 | 주식회사 엘지생활건강 | 디팔미토일 하이드록시프롤린과 갈릭산 에스터 유도체를 함유하는 화장료 조성물 |
CA2987242C (en) | 2015-05-25 | 2023-10-10 | Isotherapeutics Group, Llc | Dotmp kit formulations for radioisotopes |
WO2019099995A1 (en) * | 2017-11-17 | 2019-05-23 | Neurana Pharmaceuticals, Inc. | Methods of administering tolperisone |
CA3087698A1 (en) | 2018-01-05 | 2019-07-11 | Impel Neuropharma, Inc. | Intranasal delivery of olanzapine by precision olfactory device |
US10896106B2 (en) * | 2018-05-10 | 2021-01-19 | Teradyne, Inc. | Bus synchronization system that aggregates status |
US20200338090A1 (en) * | 2019-04-29 | 2020-10-29 | Marsh and Wang Medical Systems, LLC | Seizure control compositions and methods of using same |
CN110420190B (zh) * | 2019-08-29 | 2021-07-09 | 湖南洞庭药业股份有限公司 | 氯硝西泮片及其制备方法 |
CA3221395A1 (en) * | 2021-06-10 | 2022-12-15 | Neurelis, Inc. | Methods and compositions for treating seizure disorders in pediatric patients |
US11583510B1 (en) | 2022-02-07 | 2023-02-21 | Flamel Ireland Limited | Methods of administering gamma hydroxybutyrate formulations after a high-fat meal |
CN114656410A (zh) * | 2022-03-02 | 2022-06-24 | 济南同路医药科技发展有限公司 | 一种氯硝西泮杂质及其制备方法 |
Family Cites Families (35)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5266466A (en) * | 1987-01-14 | 1993-11-30 | President And Fellows Of Harvard College | Method of using T7 DNA polymerase to label the 3' end of a DNA molecule |
SE8800080L (sv) | 1988-01-13 | 1989-07-14 | Kabivitrum Ab | Laekemedelskomposition |
US4950664A (en) | 1988-09-16 | 1990-08-21 | Rugby-Darby Group Companies, Inc. | Nasal administration of benzodiazepine hypnotics |
FR2656303B1 (fr) | 1989-12-26 | 1994-06-10 | Parke Davis | Solution buvable d'un derive des benzodiazepines et son application pharmacologique. |
EP0532546B1 (en) * | 1990-05-10 | 1998-03-18 | Bechgaard International Research And Development A/S | A pharmaceutical preparation containing n-glycofurols and n-ethylene glycols |
DE4021263C2 (de) | 1990-07-04 | 1996-04-11 | Pfeiffer Erich Gmbh & Co Kg | Austragvorrichtung für Medien |
FR2692174B1 (fr) | 1992-06-16 | 1994-08-19 | Valois | Dispositif à gaz comprimé pour projeter sous forme finement divisée une dose unique d'une substance fluide. |
DK17093D0 (da) | 1993-02-15 | 1993-02-15 | Lyfjathroun H F | Farmaceutisk praeparat til topisk administrering af antigener og/eller vacciner til pattedyr via slimhinder |
AU2345695A (en) * | 1994-04-28 | 1995-11-29 | F. Hoffmann-La Roche Ag | Pharmaceutical composition for transdermal delivery |
GB9409778D0 (en) | 1994-05-16 | 1994-07-06 | Dumex Ltd As | Compositions |
US20050163719A1 (en) | 1997-10-01 | 2005-07-28 | Dugger Harry A.Iii | Buccal, polar and non-polar spray containing diazepam |
DE19756442A1 (de) | 1997-12-18 | 1999-06-24 | Pfeiffer Erich Gmbh & Co Kg | Spender für Medien |
US6699849B1 (en) * | 1998-02-23 | 2004-03-02 | Cyclops, Ehf. | Cyclodextrin complexes of benzodiazepines |
SE9803240D0 (sv) | 1998-09-24 | 1998-09-24 | Diabact Ab | A pharmaceutical composition having a rapid action |
GB9826192D0 (en) | 1998-12-01 | 1999-01-20 | Controlled Theraputics Scotlan | Oral transmucosal delivery |
ES2304969T3 (es) * | 1999-07-26 | 2008-11-01 | Sk Holdings Co., Ltd. | Composiciones anticonvulsivas transnasales. |
DE19938798A1 (de) | 1999-08-16 | 2001-03-01 | Pfeiffer Erich Gmbh & Co Kg | Spender für Flüssigkeiten oder für zähflüssige oder versprühbare Produkte |
DE19940236A1 (de) | 1999-08-25 | 2001-03-08 | Pfeiffer Erich Gmbh & Co Kg | Spender mit manuell betätigbarer Ausbringeinrichtung |
US6610271B2 (en) | 2000-05-10 | 2003-08-26 | University Of Kentucky Research Foundation | System and method for intranasal administration of lorazepam |
ATE355854T1 (de) | 2000-08-03 | 2007-03-15 | Antares Pharma Ipl Ag | Neue zusammensetzung zur transdermalen und/oder transmukosalen wirkstoffanwendung mit geeignetem therapeutischen spiegel |
FR2815611B1 (fr) | 2000-10-23 | 2003-04-11 | Valois Sa | Tete de distribution et distributeur de produit fluide comportant une telle tete de distribution |
US20040176359A1 (en) * | 2001-02-20 | 2004-09-09 | University Of Kentucky Research Foundation | Intranasal Benzodiazepine compositions |
CA2456754A1 (en) * | 2001-08-08 | 2003-02-20 | Yuji Iizawa | Benzazepine derivative, process for producing the same, and use |
US20050063940A1 (en) | 2002-02-25 | 2005-03-24 | Sveinbjorn Gizurarson | Bioadhesive agent |
US6742677B2 (en) | 2002-04-18 | 2004-06-01 | Valois S.A.S. | Fluid dispenser pump |
AU2003233653B2 (en) * | 2002-05-23 | 2008-08-07 | Umd, Inc. | Compositions and method for transmucosal drug delivery and cryoprotection |
US6855332B2 (en) | 2002-07-03 | 2005-02-15 | Lyfjathroun Hf. | Absorption promoting agent |
ITRM20020357A1 (it) | 2002-07-03 | 2004-01-05 | Foscama Biomed Chim Farma | Composizione liquida per la somministrazione orale di lorazepam. |
ATE329594T1 (de) | 2003-01-31 | 2006-07-15 | Orexo Ab | Schnell wirkende pharmazeutische zusammensetzung |
BRPI0411572A (pt) | 2003-06-17 | 2006-08-08 | Sk Corp | microemulsões transnasais contendo diazepam |
EP1670433B1 (en) * | 2003-10-10 | 2011-11-23 | Antares Pharma IPL AG | Transdermal pharmaceutical formulation for minimizing skin residues |
EP1848403B8 (en) | 2005-01-14 | 2010-05-19 | Camurus Ab | Topical bioadhesive formulations |
US20070021411A1 (en) | 2005-05-11 | 2007-01-25 | Cloyd James C | Supersaturated benzodiazepine solutions and their delivery |
TW200824693A (en) | 2006-08-28 | 2008-06-16 | Jazz Pharmaceuticals Inc | Pharmaceutical compositions of clonazepam and methods of use thereof |
US9319244B2 (en) | 2010-12-22 | 2016-04-19 | Usablenet Inc. | Methods for emailing labels as portable data files and devices thereof |
-
2007
- 2007-08-14 TW TW096130010A patent/TW200824693A/zh unknown
- 2007-08-23 PE PE2007001144A patent/PE20081361A1/es not_active Application Discontinuation
- 2007-08-27 MX MX2009002310A patent/MX2009002310A/es not_active Application Discontinuation
- 2007-08-27 KR KR1020097006303A patent/KR20090043603A/ko not_active Application Discontinuation
- 2007-08-27 NZ NZ595388A patent/NZ595388A/en not_active IP Right Cessation
- 2007-08-27 CN CN2007800399467A patent/CN101528261B/zh not_active Expired - Fee Related
- 2007-08-27 UY UY30561A patent/UY30561A1/es unknown
- 2007-08-27 BR BRPI0714907-7A patent/BRPI0714907A2/pt not_active IP Right Cessation
- 2007-08-27 NZ NZ575744A patent/NZ575744A/en not_active IP Right Cessation
- 2007-08-27 US US11/897,028 patent/US8609651B2/en not_active Expired - Fee Related
- 2007-08-27 AU AU2007290589A patent/AU2007290589B2/en not_active Ceased
- 2007-08-27 CA CA002662197A patent/CA2662197A1/en not_active Abandoned
- 2007-08-27 JP JP2009526675A patent/JP2010502612A/ja not_active Ceased
- 2007-08-27 US US11/897,002 patent/US8716279B2/en not_active Expired - Fee Related
- 2007-08-27 EP EP07837400A patent/EP2068933A2/en not_active Withdrawn
- 2007-08-27 JP JP2009526683A patent/JP2010502614A/ja not_active Ceased
- 2007-08-27 WO PCT/US2007/018942 patent/WO2008027395A2/en active Application Filing
- 2007-08-27 WO PCT/US2007/018877 patent/WO2008027357A2/en active Application Filing
- 2007-08-27 EP EP07811570A patent/EP2056877A2/en not_active Withdrawn
- 2007-08-28 AR ARP070103802A patent/AR062556A1/es not_active Application Discontinuation
-
2009
- 2009-02-26 IL IL197275A patent/IL197275A0/en unknown
- 2009-03-23 NO NO20091211A patent/NO20091211L/no not_active Application Discontinuation
Cited By (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11504347B1 (en) | 2016-07-22 | 2022-11-22 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
US11602513B1 (en) | 2016-07-22 | 2023-03-14 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
US11602512B1 (en) | 2016-07-22 | 2023-03-14 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
US11766418B2 (en) | 2016-07-22 | 2023-09-26 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
US11826335B2 (en) | 2016-07-22 | 2023-11-28 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
US11839597B2 (en) | 2016-07-22 | 2023-12-12 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
US11896572B2 (en) | 2016-07-22 | 2024-02-13 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
US11986451B1 (en) | 2016-07-22 | 2024-05-21 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
US11400065B2 (en) | 2019-03-01 | 2022-08-02 | Flamel Ireland Limited | Gamma-hydroxybutyrate compositions having improved pharmacokinetics in the fed state |
US11779557B1 (en) | 2022-02-07 | 2023-10-10 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
Also Published As
Publication number | Publication date |
---|---|
WO2008027395A2 (en) | 2008-03-06 |
NZ595388A (en) | 2011-12-22 |
US8609651B2 (en) | 2013-12-17 |
PE20081361A1 (es) | 2008-11-06 |
US20080076761A1 (en) | 2008-03-27 |
WO2008027357A2 (en) | 2008-03-06 |
MX2009002310A (es) | 2009-09-21 |
NZ575744A (en) | 2011-10-28 |
CN101528261A (zh) | 2009-09-09 |
EP2056877A2 (en) | 2009-05-13 |
WO2008027395A3 (en) | 2008-04-17 |
CA2662197A1 (en) | 2008-03-06 |
JP2010502614A (ja) | 2010-01-28 |
AU2007290589A1 (en) | 2008-03-06 |
TW200824693A (en) | 2008-06-16 |
IL197275A0 (en) | 2009-12-24 |
WO2008027357A3 (en) | 2008-04-17 |
US8716279B2 (en) | 2014-05-06 |
EP2068933A2 (en) | 2009-06-17 |
AR062556A1 (es) | 2008-11-19 |
AU2007290589B2 (en) | 2012-04-05 |
BRPI0714907A2 (pt) | 2014-08-19 |
US20080070904A1 (en) | 2008-03-20 |
WO2008027357A9 (en) | 2009-04-30 |
UY30561A1 (es) | 2008-03-31 |
KR20090043603A (ko) | 2009-05-06 |
JP2010502612A (ja) | 2010-01-28 |
CN101528261B (zh) | 2012-07-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NO20091211L (no) | Farmasoytiske clonazepamformuleringer og fremgangsmate for disse | |
MA33044B1 (fr) | Composition pharmaceutique contenant des derives de glucopyranosyl diphenylmethane, sa forme posologique galenique, son procede de preparation et ses utilisations pour une regulation glycemique amelioree chez un patient | |
WO2007143607A3 (en) | Method of treating atrophic vaginitis | |
NO20060978L (no) | Farmasoytiske blandingr for behandling av prematur ejakulasjon ved pulmonal inhalering | |
NO20055129L (no) | Fenylsubstituerte karboksylsyrer | |
NO20090157L (no) | Tienpyrimidiner anvendelige som modulatorer av ionekanaler | |
PL360495A1 (en) | Arylmethylamine derivatives for use as tryptase inhibitors | |
BRPI0515931A (pt) | compostos, processo para a sua preparação, composições farmacêuticas que os compreendem, método para o tratamento e/ou profilaxia de enfermidades e utilização desses compostos | |
NO20054769L (no) | Substituerte fenylalkansyrer | |
TR200201004T2 (tr) | Monoamin reuptake önleyicileri olarak biaril eter türevleri | |
ATE411280T1 (de) | Phenoxyessigsäure-derivate zur behandlung von störungen der atemwege | |
NO20084826L (no) | Ny administrasjonsform av racecadotril | |
UA94749C2 (en) | Benzimidazole modulators of vr1 | |
UA92636C2 (en) | Tetrahydro-pyrimidoazepines as modulators of trpv1 | |
NO20092464L (no) | Faste former av rasemisk ilaprazol | |
MX344787B (es) | Composiciones que contienen berberina o analogos de la misma para tratar rosacea o trastornos de la piel relacionados con enrojecimiento de la cara. | |
NO20083836L (no) | N-hydroksyakrylamidforbindelser | |
BR0313718A (pt) | Composto, processo para a preparação do mesmo, composição farmacêutica, métodos para tratar um indivìduo humano ou animal sofrendo de uma condição que é mediada por cox-2 e para tratar um indivìduo humano ou animal sofrendo de um distúrbio inflamatório, e, uso de um composto | |
EA200201276A1 (ru) | Производные арилметиламина для использования в качестве ингибиторов триптазы | |
MX2009005245A (es) | Metodo de tratamiento para la enfermedad intestinal inflamatoria. | |
BRPI0511714A (pt) | composto ou um sal farmaceuticamente aceitável do mesmo, composição farmacêutica, e, método para tratar uma doença em um animal | |
PL379512A1 (pl) | Nowe metody i ich zastosowanie | |
WO2007149816A3 (en) | Strontium compositions and methods of treating osteoporotic conditions | |
UA100326C2 (uk) | Мазь для місцевого лікування геморою | |
NO20030155L (no) | Farmasöytiske sammensetninger og fremgangsmåter for anvendelse derav |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FC2A | Withdrawal, rejection or dismissal of laid open patent application |